Drug Profile
NAL 3223
Alternative Names: NAL3223Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Anti-infectives; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Herpes zoster
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Herpes-zoster in Unknown (Transdermal, Patch)
- 17 Aug 2016 NAL 3223 is available for licensing as of 17 Aug 2016. http://www.nalpharma.com/licensing.php?id=10&lang=en
- 17 Aug 2016 Clinical trials in Herpes zoster (Transdermal)